GENB·Generate Biomedicines, Inc.
GENB|Analyst Targets
GENB|Insider Trading
GENB|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $-0.55 | - | - |
| Q1'26 | $-0.51 | $-1.07 | -111.2% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $8M | - | - |
| Q1'26 | - | $7M | - |
GENB|Monthly Returns
Market Data
GENB Stock Snapshot
- Market cap
- 1.82B
- Day range
- $12.47 – $13.43
- News sentiment
- 62/100 · Bullish
- Analyst target
- $27.00 (+107.7%)
- Consensus
- Buy · 14 analysts
The technical read on GENB is balanced, which usually means the market is waiting on a catalyst. Thinner liquidity means moves can extend past what the fundamentals alone justify.
Sector Rotation
Is money rotating into or out of GENB's sector?
Generate Biomedicines, Inc. sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, GENB ranks 7th of 15 tracked industries, weakening.
- Sector rank
- #1 of 12
- Sector state
- Weakening
- Sector rotation score
- 100
- Industry rank
- #7 of 15
Analyst Consensus Estimates
What do analysts expect GENB to earn?
Analysts expect Generate Biomedicines, Inc. to earn -$2.30 per share in the fiscal year ending Dec 2026 and -$2.28 in the fiscal year ending Dec 2027, from 4 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.
Analyst Rating Changes
Are analysts turning bullish or bearish on GENB?
HC Wainwright & Co. most recently reiterated its rating on Generate Biomedicines, Inc. to Buy on Oct 5, 2026 with a price target of $30. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- HC Wainwright & Co.: Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Corporate Stakes
Which companies own a stake in GENB?
NVIDIA Corporation reports a stake in Generate Biomedicines, Inc. on SEC Form 13F: 833.3K shares, about 0.60% of the company, worth $14.1M at the end of Q2 2026. At today's price that stake is worth $10.8M, about 0.00% of NVDA's own market value.
- Holder
- NVDA
- Shares held
- 833.3K
- Stake
- 0.60%
- Value
- $14.1M
Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.
Earnings Release, Scored
What did Generate Biomedicines, Inc.'s latest earnings release say?
Most important lines
- 1
Revenue for the quarter ended June 30, 2026, was $6.3 million, compared with $10.1 million for the same period in 2025.
- 2
Net loss was $67.3 million for the quarter ended June 30, 2026, compared with $56.7 million for the same period in 2025, which includes noncash, stock-based compensation expense of $8.2 million and $5.5 million, respectively.
Negative tone - 3
Net cash used in operating activities was $138.3 million for the six months ended June 30, 2026, compared with $101.9 million for the six months ended June 30, 2025.
ETF holders
ETFs holding GENB
Top ETF holdersWeight
News & sentiment
What is the news saying about GENB?
GENB fell 7.1% over the month to Nov 6. Daily news tone ranged from 48 to 96 and read 50 on Oct 28.
- Oct 27 +9.1%
- Oct 28 +15.1%same day: Anthropic Says Claude Helped Generate 35,000 Drug Designs, Cut Drug Development Workloads
- Nov 5 -11.2%
Technical analysis
How strong is GENB's momentum right now?
On the daily chart GENB ranks at the 50th percentile for momentum against the stocks and ETFs DailyIQ tracks, a neutral reading.
Institutional ownership
Are big funds buying or selling GENB?
28 of the 39 tracked managers added to GENB in their latest 13F and 9 trimmed. Together they own 4.3% of the company, worth $101.2M. Baker Bros. Advisors and ARK Investment Management alone hold 1.9%.
- 1Baker Bros. Advisors LP1.02%$24.0M positionUnchanged last quarter
- $21.7M positionAdded 157.7% last quarter
- $19.1M positionAdded 762.6% last quarter
- 4State Street Corp0.38%$8.9M positionNew position last quarter
- 5UBS Group AG0.23%$5.5M positionTrimmed 8.5% last quarter
- $3.8M positionNew position last quarter
- $3.0M positionAdded 904.6% last quarter
- $2.8M positionNew position last quarter
- 9Barclays PLC0.08%$2.0M positionAdded 64.9% last quarter
- 10LMR Partners LLP0.07%$1.7M positionUnchanged last quarter
Discover more
How has GENB done against its peers?
Over the six months to Nov 6, GENB returned −13.3%. Of the 15 related stocks and ETFs, 14 did better, led by MRNA at +426.3%.
- 1MRNAModerna, Inc.up 426.3%+439.6 pts
- 2ARKGARK Genomic Revolution ETFup 46.0%+59.3 pts
- 3AMGNAmgen Inc.up 39.2%+52.5 pts
- 4ROIVRoivant Sciences Ltd.up 36.9%+50.3 pts
- 5RPRXRoyalty Pharma plcup 34.5%+47.9 pts
- 6BIIBBiogen Inc.up 30.4%+43.7 pts
- 7RVMDRevolution Medicines, Inc.up 29.1%+42.4 pts
- 8VRTXVertex Pharmaceuticals Incorporatedup 28.0%+41.3 pts
- 15GENBThis stockdown 13.3%
- 16INSMInsmed Incorporateddown 20.8%−7.5 pts